Hypertension in CKD Market, By Drug Class, By Distribution Channel, By Geography

Description

Hypertension in CKD Market is estimated to be valued at USD 345.2 Mn in 2026 and is expected to reach USD 712.2 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.9% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 345.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	10.90%	2033 Value Projection:	USD 712.2 Mn

Persons with CKD have significantly higher rates of morbidity, mortality, hospitalizations, and healthcare utilization. Chronic kidney disease may be caused due to comorbid conditions such as high blood pressure, etc. This can lead to buildup of metabolic wastes in patient's blood and make them feel sick. Chronic kidney disease complications include high blood pressure, anemia (low blood count), weak bones, poor nutritional health, and nerve damage. Chronic kidney disease also increases the risk of developing heart and blood vessel diseases such as heart attack, stroke, etc. These problems may happen slowly over a long period of time.

Market Dynamics

Key players are involved in announcing their results for the clinical trials conducted for the antihypertensive drugs, in order to find the treatment for hypertension in patients suffering from chronic kidney disease. For instance, in 2018, Novartis International AG announced positive results for Entresto (sacubitril/valsartan). According to the clinical trials conducted by the company, it was found that Entresto (sacubitril/valsartan) helped to preserve kidney function in patients suffering from cardiovascular diseases. Moreover, Entresto (sacubitril/valsartan) belongs to angiotensin receptor blockers (ARBs) drug class.

The increasing number of patients undergoing dialysis treatment is expected to drive growth of the global hypertension in CKD market. For instance, according to the data published in the Indian Journal of Public Health (IJPH), in 2018, around 130,000 patients received dialysis treatment in India and the number increased by around 232 patients per million population in India as compared to 2017.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global hypertension in CKD market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global hypertension in CKD market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the hypertension in CKD market

Detailed Segmentation:

Global Hypertension in CKD Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
Diuretics
RAS Blockade
B - Blockers
Calcium Channel Blockers
Others
Global Hypertension in CKD Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hypertension in CKD Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Drug Class:
  - Diuretics
  - RAS Blockade
  - B - Blockers
  - Calcium Channel Blockers
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - U.S.
  - Canada
Latin America
- By Drug Class:
  - Diuretics
  - RAS Blockade
  - B - Blockers
  - Calcium Channel Blockers
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Drug Class:
  - Diuretics
  - RAS Blockade
  - B - Blockers
  - Calcium Channel Blockers
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - U.K.
  - Germany
  - Italy
  - Spain
  - France
  - Russia
  - Rest of Europe
Asia Pacific
- By Drug Class:
  - Diuretics
  - RAS Blockade
  - B - Blockers
  - Calcium Channel Blockers
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - Australia
  - India
  - China
  - Japan
  - ASEAN
  - South Korea
  - Rest of Asia Pacific
Middle East
- By Drug Class:
  - Diuretics
  - RAS Blockade
  - B - Blockers
  - Calcium Channel Blockers
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Drug Class:
  - Diuretics
  - RAS Blockade
  - B - Blockers
  - Calcium Channel Blockers
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Sanofi S.A*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
Teva Pharmaceutical Industries Ltd.
Eli Lilly and Company
AstraZeneca Plc
Novartis International AG
H. Boehringer Sohn AG & Ko. KG
Kissei Pharmaceutical Co., Ltd.
Reata Pharmaceuticals, Inc.
Ardelyx,
KBP Biosciences Holdings Limited

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI4431

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Key Developments
Pipeline analysis
Regulatory Scenario
Key Developments
Treatment Approaches
PEST Analysis

4. Global Hypertension in CKD Market, By Drug Class, 2021 - 030, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
RAS Blockade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
β-Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Others (α-Blockers, Vasodilators, Proteinuria, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends

5. Global Hypertension in CKD Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

6. Global Hypertension in CKD Market, By Region, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2021 -2033, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Company Profiles
- Sanofi S.A
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eli Lilly and Company
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AstraZeneca Plc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis International AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- KBP Biosciences Holdings Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Ardelyx
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Reata Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Kissei Pharmaceutical Co., Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bayer Pharmaceuticals, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- GSK plc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies

8. Section

References
Research Methodology
About us and Sales Contact